Instituto Rosenbusch S.A. (ROSE) - Total Assets

Latest as of December 2025: AR$7.75 Billion ARS ≈ $5.60 Million USD

Based on the latest financial reports, Instituto Rosenbusch S.A. (ROSE) holds total assets worth AR$7.75 Billion ARS (≈ $5.60 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Instituto Rosenbusch S.A. - Total Assets Trend (2000–2025)

This chart illustrates how Instituto Rosenbusch S.A.'s total assets have evolved over time, based on quarterly financial data. Also see ROSE stock market capitalisation for the company's overall valuation and market capitalisation.

Instituto Rosenbusch S.A. - Asset Composition Analysis

Current Asset Composition (December 2025)

Instituto Rosenbusch S.A.'s total assets of AR$7.75 Billion consist of 74.0% current assets and 26.0% non-current assets. Review how much debt does Instituto Rosenbusch S.A. carry to assess the company's total debt and financial obligations.

Asset Category Amount (ARS) % of Total Assets
Cash & Equivalents AR$0.00 9.2%
Accounts Receivable AR$1.19 Billion 15.4%
Inventory AR$2.61 Billion 33.7%
Property, Plant & Equipment AR$0.00 0.0%
Intangible Assets AR$0.00 0.0%
Goodwill AR$0.00 0.0%

Asset Composition Trend (2000–2025)

This chart illustrates how Instituto Rosenbusch S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ROSE stock price and chart for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Instituto Rosenbusch S.A.'s current assets represent 74.0% of total assets in 2025, an increase from 0.0% in 2000.
  • Cash Position: Cash and equivalents constituted 9.2% of total assets in 2025, up from 1.4% in 2000.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2000.
  • Asset Diversification: The largest asset category is inventory at 33.7% of total assets.

Instituto Rosenbusch S.A. Competitors by Total Assets

Key competitors of Instituto Rosenbusch S.A. based on total assets are shown below.

Company Country Total Assets
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Germany €1.60 Trillion
GALDERMA GROUP AG
NYSE:GALDY
USA $13.39 Billion
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
USA $15.42 Trillion
Beijing Tongrentang Co Ltd
SHG:600085
China CN¥31.82 Billion
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥30.77 Billion
Neuland Laboratories Limited
NSE:NEULANDLAB
India Rs29.30 Billion
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
China CN¥17.01 Billion

Instituto Rosenbusch S.A. - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.87 1.79 1.04
Quick Ratio 0.47 0.86 0.45
Cash Ratio 0.00 0.00 0.00
Working Capital AR$-872.37 Million AR$3.43 Billion AR$19.50 Million

Instituto Rosenbusch S.A. - Advanced Valuation Insights

This section examines the relationship between Instituto Rosenbusch S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 19.15
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) -21.9%
Total Assets AR$7.75 Billion
Market Capitalization $4.78 Million USD

Valuation Analysis

Below Book Valuation: The market values Instituto Rosenbusch S.A.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Instituto Rosenbusch S.A.'s assets decreased by 21.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Instituto Rosenbusch S.A. (2000–2025)

The table below shows the annual total assets of Instituto Rosenbusch S.A. from 2000 to 2025.

Year Total Assets Change
2025-12-31 AR$7.75 Billion
≈ $5.60 Million
-21.93%
2024-12-31 AR$9.92 Billion
≈ $7.18 Million
-9.65%
2023-12-31 AR$10.98 Billion
≈ $7.95 Million
+714.64%
2022-12-31 AR$1.35 Billion
≈ $975.41K
+80.38%
2021-12-31 AR$747.29 Million
≈ $540.74K
+10.60%
2020-12-31 AR$675.64 Million
≈ $488.90K
+35.96%
2019-12-31 AR$496.94 Million
≈ $359.59K
+35.50%
2018-12-31 AR$366.76 Million
≈ $265.39K
+71.76%
2017-12-31 AR$213.52 Million
≈ $154.51K
+7.92%
2016-12-31 AR$197.86 Million
≈ $143.17K
+19.07%
2015-12-31 AR$166.17 Million
≈ $120.24K
+18.06%
2014-12-31 AR$140.75 Million
≈ $101.85K
+11.81%
2013-12-31 AR$125.89 Million
≈ $91.09K
+9.57%
2012-12-31 AR$114.90 Million
≈ $83.14K
+32.18%
2011-12-31 AR$86.92 Million
≈ $62.90K
+18.38%
2010-12-31 AR$73.42 Million
≈ $53.13K
+13.87%
2009-12-31 AR$64.48 Million
≈ $46.66K
+12.26%
2008-12-31 AR$57.44 Million
≈ $41.56K
+6.71%
2007-12-31 AR$53.83 Million
≈ $38.95K
+10.94%
2006-12-31 AR$48.52 Million
≈ $35.11K
+6.48%
2005-12-31 AR$45.57 Million
≈ $32.97K
+16.50%
2004-12-31 AR$39.12 Million
≈ $28.30K
+9.89%
2003-12-31 AR$35.60 Million
≈ $25.76K
+20.45%
2002-12-31 AR$29.55 Million
≈ $21.38K
+92.70%
2001-12-31 AR$15.34 Million
≈ $11.10K
+4.25%
2000-12-31 AR$14.71 Million
≈ $10.64K
--

About Instituto Rosenbusch S.A.

BA:ROSE Argentina Drug Manufacturers - Specialty & Generic
Market Cap
$4.78 Million
AR$6.60 Billion ARS
Market Cap Rank
#28774 Global
#77 in Argentina
Share Price
AR$155.00
Change (1 day)
+1.64%
52-Week Range
AR$119.50 - AR$327.00
All Time High
AR$380.00
About

Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious kera… Read more